{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:02:49Z","timestamp":1792785769593,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3564,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1093\/annonc\/mdp358","type":"journal-article","created":{"date-parts":[[2009,8,28]],"date-time":"2009-08-28T20:46:15Z","timestamp":1251492375000},"page":"498-505","source":"Crossref","is-referenced-by-count":32,"title":["Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)\u2014a randomised controlled trial of exemestane versus continued tamoxifen after 2\u20133 years tamoxifen"],"prefix":"10.1016","volume":"21","author":[{"given":"G.","family":"Bertelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ireland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.F.","family":"Snowdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Drosik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Karnicka-Mlodkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.C.","family":"Coombes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp358_bb0010","first-page":"257","article-title":"Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature","volume":"26","author":"Machado","year":"2005","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1093\/annonc\/mdp358_bb0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ygyno.2004.03.048","article-title":"Endometrial pathologies associated with postmenopausal tamoxifen treatment","volume":"94","author":"Cohen","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdp358_bb0020","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdp358_bb0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(05)78216-7","article-title":"Should tamoxifen users be screened for endometrial lesions?","volume":"351","author":"Neven","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdp358_bb0030","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1001\/jama.280.17.1510","article-title":"Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities","volume":"280","author":"Smith-Bindman","year":"1998","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdp358_bb0035","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/09513590500430450","article-title":"Endometrial thickness of postmenopausal breast cancer patients treated with tamoxifen","volume":"21","author":"Salazar","year":"2005","journal-title":"Gynecol Endocrinol"},{"key":"10.1093\/annonc\/mdp358_bb0040","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/13697139809085539","article-title":"Uterine surveillance of asymptomatic postmenopausal women taking tamoxifen","volume":"1","author":"Gardner","year":"1998","journal-title":"Climacteric"},{"key":"10.1093\/annonc\/mdp358_bb0045","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1200\/JCO.1999.17.7.2050","article-title":"Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening","volume":"17","author":"Love","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp358_bb0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/gyno.1998.5316","article-title":"Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen","volume":"73","author":"Mourits","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdp358_bb0055","first-page":"363","article-title":"Transvaginal endometrial sonography in postmenopausal women taking tamoxifen","volume":"93","author":"Tesoro","year":"1999","journal-title":"Obstet Gynecol"},{"key":"10.1093\/annonc\/mdp358_bb0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1005820115535","article-title":"Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients","volume":"47","author":"Bertelli","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp358_bb0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1006\/gyno.1994.1029","article-title":"Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients","volume":"52","author":"Cohen","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdp358_bb0070","first-page":"660","article-title":"Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen","volume":"81","author":"Lahti","year":"1993","journal-title":"Obstet Gynecol"},{"key":"10.1093\/annonc\/mdp358_bb0075","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1054\/brst.1999.0160","article-title":"Thickened endometrium caused by tamoxifen returns to normal following tamoxifen cessation","volume":"9","author":"Love","year":"2000","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdp358_bb0080","first-page":"321","article-title":"Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients","volume":"25","author":"Menada","year":"2004","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1093\/annonc\/mdp358_bb0085","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1471-0528.2000.tb11104.x","article-title":"Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients","volume":"107","author":"Cohen","year":"2000","journal-title":"BJOG"},{"key":"10.1093\/annonc\/mdp358_bb0090","first-page":"674","article-title":"Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen","volume":"39","author":"Bornstein","year":"1994","journal-title":"J Reprod Med"},{"key":"10.1093\/annonc\/mdp358_bb0095","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1097\/00006250-200606000-00057","article-title":"ACOG committee opinion. No. 336: tamoxifen and uterine cancer","volume":"107","author":"American College of Obstetricians and Gynecologists Committee on Gynecologic Practice","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1093\/annonc\/mdp358_bb0100","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/1097-0142(20000815)89:4<800::AID-CNCR12>3.0.CO;2-Y","article-title":"Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study","volume":"89","author":"Althuis","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp358_bb0105","first-page":"2089","article-title":"In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients","volume":"4","author":"Geisler","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp358_bb0110","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.2002.20.3.751","article-title":"Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomised, cross-over-designed study","volume":"20","author":"Geisler","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdp358_bb0115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists\u2019 Group","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdp358_bb0120","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp358_bb0125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2\u20133 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdp358_bb0130","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp358_bb0135","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2005.03.3654","article-title":"Quality of life in the Intergroup Exemestane Study: a randomised trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer","volume":"24","author":"Fallowfield","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp358_bb0140","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdp358_bb0145","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/1078-0432.CCR-05-0225","article-title":"Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology","volume":"12","author":"Gerber","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdp358_bb0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-006-9285-x","article-title":"Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients","volume":"101","author":"Markovitch","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1093\/annonc\/mdp358_bb0155","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/annonc\/mdi021","article-title":"Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients","volume":"16","author":"Morales","year":"2005","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdp358_bb0160","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ygyno.2006.04.004","article-title":"Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors","volume":"103","author":"Garuti","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdp358_bb0165","first-page":"69","article-title":"Reversal of tamoxifen induced endometrial modifications by switching to letrozole: a prospective transvaginal ultrasound (TVUS) study in early breast cancer patients","volume":"22","author":"Garrone","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdp358_bb0170","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/humrep\/deh567","article-title":"The ATAC (\u2018Arimidex\u2019, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy","volume":"20","author":"Duffy","year":"2005","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1093\/annonc\/mdp358_bb0175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejogrb.2006.04.001","article-title":"Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer","volume":"132","author":"Garuti","year":"2007","journal-title":"Eur J Obstet Gynecol Reprod Biol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419383139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419383139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/3\/498\/397828\/mdp358.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:14:49Z","timestamp":1624504489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419383139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0923753419383139"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp358","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}